EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-inflammatory potential of simvastatin and amfenac in ARPE-19 cells; insights in preventing re-detachment and proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery

Niina Harju, Maria Hytti, Onni Kolari, Hilkka Nisula, Sirpa Loukovaara, Anu Kauppinen

International Ophthalmology · 26.03.2024 · 44 (1)

DOI: 10.1007/s10792-024-03067-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Ophthalmology, online erschienen am 26.03.2024. Verfasst von Niina Harju und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland. niina.harju@uef.fi. Hauptthemen laut MEDLINE: Vitreoretinopathy, Proliferative, Retinal Detachment, Phenylacetates. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helsinki University Hospital grant, Finnish Pharmaceutical Society, Päivikki and Sakari Sohlberg Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Rhegmatogenous retinal detachment is a severe vision-threatening complication that can result into proliferative vitreoretinopathy (PVR) and re-detachment of the retina if recovery from surgery fails. Inflammation and changes in retinal pigment epithelial (RPE) cells are important contributors to the disease. Here, we studied the effects of simvastatin and amfenac on ARPE-19 cells under inflammatory conditions.

Methods

ARPE-19 cells were pre-treated with simvastatin and/or amfenac for 24 h after which interleukin (IL)-1α or IL-1β was added for another 24 h. After treatments, lactate dehydrogenase release, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) processing, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activity, prostaglandin E2 (PGE2) level, and extracellular levels of IL-6, IL-8, monocytic chemoattractant protein (MCP-1), vascular endothelial growth factor (VEGF), and pigment epithelium-derived factor, as well as the production of reactive oxygen species (ROS) were determined.

Results

Pre-treatment of human ARPE-19 cells with simvastatin reduced the production of IL-6, IL-8, and MCP-1 cytokines, PGE2 levels, as well as NF-κB activity upon inflammation, whereas amfenac reduced IL-8 and MCP-1 release but increased ROS production. Together, simvastatin and amfenac reduced the release of IL-6, IL-8, and MCP-1 cytokines as well as NF-κB activity but increased the VEGF release upon inflammation in ARPE-19 cells.

Conclusion

Our present study supports the anti-inflammatory capacity of simvastatin as pre-treatment against inflammation in human RPE cells, and the addition of amfenac complements the effect. The early modulation of local conditions in the retina can prevent inflammation induced PVR formation and subsequent retinal re-detachment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vitreoretinopathy, ProliferativeRetinal DetachmentPhenylacetatesHumansNF-kappa BVascular Endothelial Growth Factor ARetinal Pigment EpitheliumSimvastatinReactive Oxygen SpeciesDinoprostoneInterleukin-6Interleukin-8CytokinesAnti-Inflammatory AgentsInflammation

Stichwörter der Autor:innen

AmfenacInflammationProliferative vitreoretinopathyRPE cellsRhegmatogenous retinal detachmentSimvastatin

Substanzen

NF-kappa BVascular Endothelial Growth Factor AamfenacSimvastatinReactive Oxygen SpeciesDinoprostoneInterleukin-6Interleukin-8CytokinesAnti-Inflammatory Agents

Autor:innen und Institutionen

  • School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland. niina.harju@uef.fi.
  • Head and Neck Center, Ophthalmology Research Unit, Helsinki University Central Hospital, Helsinki, Finland. niina.harju@uef.fi.
  • School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
  • Department of Ophthalmology, School of Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
  • Department of Ophthalmology, Unit of Vitreoretinal Surgery, and Individualized Drug Therapy Research Program, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.
  • School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland. anu.kauppinen@uef.fi.

Förderung

  • Helsinki University Hospital grant
  • Finnish Pharmaceutical Society
  • Päivikki and Sakari Sohlberg Foundation
  • Sokeain Ystävät ry
  • Silmä- ja Kudospankkisäätiö
  • Mary and Georg C. Ehrnrooth Foundation
  • Evald and Hilda Nissi Foundation
  • Emil Aaltonen Foundation

Zitieren

APA

Harju, N., Hytti, M., Kolari, O., Nisula, H., Loukovaara, S., & Kauppinen, A. (2024). Anti-inflammatory potential of simvastatin and amfenac in ARPE-19 cells; insights in preventing re-detachment and proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery. International Ophthalmology, 44(1). https://doi.org/10.1007/s10792-024-03067-z

Vancouver

Harju N, Hytti M, Kolari O, Nisula H, Loukovaara S, Kauppinen A. Anti-inflammatory potential of simvastatin and amfenac in ARPE-19 cells; insights in preventing re-detachment and proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery. International Ophthalmology. 2024;44(1). doi:10.1007/s10792-024-03067-z

BibTeX
@article{Harju2024,
  author = {Harju, Niina and Hytti, Maria and Kolari, Onni and Nisula, Hilkka and Loukovaara, Sirpa and Kauppinen, Anu},
  title = {Anti-inflammatory potential of simvastatin and amfenac in ARPE-19 cells; insights in preventing re-detachment and proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery},
  journal = {International Ophthalmology},
  year = {2024},
  volume = {44},
  number = {1},
  doi = {10.1007/s10792-024-03067-z}
}
Kostenlos starten →